Biography
Specialties
James Tsai, MD
PRESIDENT, NEW YORK EYE & EAR INFIRMARY OF MOUNT SINAI
PROFESSOR AND SYSTEM CHAIR | Ophthalmology
PRESIDENT, NEW YORK EYE & EAR INFIRMARY OF MOUNT SINAI
PROFESSOR AND SYSTEM CHAIR | Ophthalmology
Are you a patient?
View my
Are you a patient?
View my
Education
MD, Stanford University School of Medicine
Internship, General Practice, Cedars-Sinai Medical Center
Residency, Ophthalmology, USC/Doheny Eye Institute
Fellowship, Glaucoma, Bascom Palmer Eye Institute
Fellowship, Glaucoma, Moorfields Eye Hospital
Certifications
American Board of Ophthalmology
Video
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Tsai during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- ReNetX Bio
- EyeNovia
- Smartlens
- Patient Innovations
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Ocutrx
- Eyethena
- Smartlens
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Tsai during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- ReNetX Bio
- EyeNovia
- Smartlens
- Patient Innovations
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Ocutrx
- Eyethena
- Smartlens
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.